CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm. » Read More
Jim Cramer sees growth starved investors searching for growth anywhere they can. That means a massive ephemeral rotation of stocks.
After leading the market for most of 2015, biotech stocks have not participated in the latest rally, a negative omen for the group.
One CEO beat out Starbucks' Howard Schultz, Nike's Mark Parker and Salesforce.com's Marc Benioff in new performance rankings.
Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.
Feeling pretty good about these stocks
Express Scripts, the largest pharmacy benefits manager in the U.S., says it's got a plan to fight drug price increases: Refuse to pay.
Some of the names on the move ahead of the open.
Spark Therapeutics plans to file for U.S. regulatory approval next year for the first gene therapy product on the market in the U.S.
As investors brace for the worst quarterly loss for stocks in four years, not all hope may be lost, if history is any guide.
Rich Ross of Evercore ISI sees 3 catchup trades to make money during these volatile times.
Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.
"Fast Money" traders looked at how to play Walt Disney, United Continental and Biogen after recent struggles.
Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.
What to buy in biotech
Experienced investors use China-driven market selloffs to buy these quality companies.
The healthcare secular theme isn't new, but is still very much in force.
Jim Cramer dishes his opinion on caller favorite stocks, including this one that has become too hard for him.
Stocks are flat on the year, but those lucky names delivering secular growth have prospered.
The sudden decline in both media and biotech stocks had traders pressing the sell button. Yet one technician said he's buying the dip.
Jim Cramer saw that investors could not hide from big bad China on Tuesday, including Apple.